Osimertinib + CT provided EGFR L858R NSCLC cases with significantly extended PFS relative to osimertinib (HR, 0.63, 95% CI, 0.44–0.90), aumolertinib (HR, 0.54, 95% CI, 0.29–1.00.29.00), dacomitinib (HR, 0.51, 95% CI, 0.28–0.93), erlotinib + bevacizumab (HR, 0.54, 95% CI, 0.31–0.94), erlotinib + ramucirumab (HR, 0.52, 95% CI, 0.29–0.93), and gefitinib + apatinib (HR, 0.44, 95% CI, 0.23–0.83). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.